Oracef

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oracef

Oracef is a prescription medication that functions as a synthetic, single-ingredient anti-infective agent used to address bacterial infections within the body. Its general purpose is to eliminate susceptible bacteria by disrupting their fundamental structure.

Quick Facts Description
Active ingredient Cefuroxime
Form Tablet, Oral Suspension, Injectable Solution
Pharmacological class Second-Generation Cephalosporin (Antibiotic)
Common purpose Eradicating susceptible bacteria
Origin Synthetic compound

Oracef: Classification and Features of Cefuroxime

Oracef contains the active ingredient Cefuroxime, and is formally classified within the pharmacological class of β-lactam antibiotics, specifically identified as a second-generation cephalosporin. This positioning is clinically recognized for providing a broader antibacterial spectrum compared to older cephalosporins, allowing it to target a strategic array of common bacterial pathogens. This synthetic compound is crucial in human medicine as a systemic anti-infective. The Cefuroxime INN is also known by other brands, such as Ceftin and Zinnat, underscoring its established role in the treatment landscape.


Composition and Available Pharmaceutical Forms

The core chemical entity is Cefuroxime, which is a single-ingredient product available in different chemical forms depending on the necessary route of administration. For oral use, the product is formulated with the inactive prodrug form, Cefuroxime axetil, and is available as a tablet, capsule, or oral suspension. This prodrug form is pharmacologically essential as it is efficiently absorbed after ingestion and then converted into the active Cefuroxime compound within the body. Conversely, the Cefuroxime sodium salt is utilized for injectable solutions (intravenous or intramuscular administration) when rapid delivery is required.


General Therapeutic Purpose of Cefuroxime

The general role of Cefuroxime is to provide a bactericidal action, actively destroying the bacterial organisms causing an infection. It accomplishes this by selectively interfering with the synthesis of the bacterial cell wall, a critical protective component that is absent in human cells. This targeted, lethal action is the fundamental reason the medicine is used: to effectively eradicate the source of a bacterial illness and resolve the underlying condition. For instance, its utility is often noted in scenarios requiring the elimination of bacteria that affect the respiratory system.

Regulatory References

  1. MedlinePlus - Cefuroxime

What side effects are possible with Oracef?

Possible Side Effects and Safety Information

The safety profile of Cefuroxime (Oracef) is formally documented in regulatory labeling, classifying potential adverse reactions by the organ system affected and their observed frequency in clinical trials and postmarketing experience.

Documented Adverse Reactions and Frequencies

Adverse reactions are classified into frequency tiers, based on official regulatory standards:

Classification Examples of Documented Reactions
Common (ge1% to <10%) Diarrhea, Nausea, Vomiting, Headache, Dizziness, Eosinophilia, Transient rise in hepatic enzyme levels, Vaginitis.
Uncommon Positive Coombs test, Skin rash, Urticaria, Pruritus.
Incidence Not Known Anaphylactic reaction, Hepatitis, Haemolytic anaemia, Pseudomembranous colitis, Severe Cutaneous Adverse Reactions (SCARs).

Serious Adverse Reactions and Safety Constraints

The label identifies clinically significant, serious adverse reactions. These include severe, occasionally fatal hypersensitivity reactions (such as anaphylaxis) and severe skin conditions (SCARs) that have been reported from postmarketing surveillance. Severe gastrointestinal complications like Clostridioides difficile-associated diarrhea (CDAD) and pseudomembranous colitis are explicitly documented safety concerns.

Specific regulatory constraints exist, such as a contraindication for patients with a known severe hypersensitivity to Cefuroxime, other cephalosporins, or a history of a severe reaction to any other beta-lactam antibacterial agent. Safety notes also address potential neurotoxicity (including convulsions and coma) if Cefuroxime accumulates, which is a particular risk for patients with impaired renal function who require dosage adjustments. Prolonged use carries the risk of microbial overgrowth of non-susceptible organisms.

Overdose and Emergency Response

The official regulatory documentation for Oracef (Cefuroxime), which is classified as a cephalosporin, strictly defines the potential consequences of overdosage and the required emergency actions. Overexposure to the medicine may lead to severe manifestations of central nervous system (CNS) toxicity. The documented presentation of overdose is primarily characterized by cerebral irritation. This CNS irritation is officially listed as potentially resulting in serious neurological events, including the presentation of convulsions and the more severe complication of encephalopathy.

Due to the known severity of these documented outcomes, the regulatory guidance mandates that emergency medical attention be sought immediately if any symptoms of overdosage are suspected. Specific management procedures are necessary because no specific antidote is known for Cefuroxime overdosage.

Treatment is formally defined as symptomatic and supportive care. The official profile states that high serum levels of Cefuroxime can be reduced through recognized procedural interventions. These include hemodialysis and peritoneal dialysis. Furthermore, a specific consideration for management exists for patients with impaired renal function, given that drug clearance is highly dependent on kidney function. The presence of any neurological symptoms requires continuous observation and monitoring.

Therapeutic Uses of Oracef

Oracef (Cefuroxime) is used to address the symptomatic burden of specific bacterial infections across several key therapeutic areas. Its primary benefit supports the management of acute symptom manifestations, providing the assistance needed for symptom stabilization and improved patient comfort.

This medicine is generally applied in addressing conditions presenting with systemic or localized discomfort, including acute bacterial infections of the respiratory tract (pneumonia, bronchitis, sinusitis, tonsillitis), the genitourinary tract (uncomplicated UTIs, pyelonephritis), skin and soft tissues (impetigo), and specialized conditions like early Lyme disease.

Quick Fact: Relief for Localized Pain

“The medication assists with maintaining functional stability by providing supportive relief when symptoms interfere with routine activities.”

Oracef is commonly applied in scenarios where additional management of discomfort is required due to conditions such as a noticeable earache from otitis media or the painful dysuria of a urinary tract infection. It contributes to improved comfort during periods of heightened symptoms, offering symptomatic relief that helps patients cope more steadily with difficult, disruptive episodes.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Who can and cannot use Oracef? — Official Regulatory Information

The eligibility profile for Oracef (Cefuroxime) is strictly defined by regulatory documents, establishing clear patient exclusions and conditional use categories.


Contraindicated Populations

Oracef is contraindicated in patients with a known hypersensitivity to cefuroxime, to any cephalosporin antibiotic, or a history of severe allergic reaction (e.g., anaphylaxis) to any other beta-lactam antibacterial agent (like penicillins).

Age-Related Eligibility and Restrictions

  • Adults and Adolescents (mathbfge 13 years) are generally eligible for tablet formulations.
  • Infants younger than 3 months are a use-not-established group for oral forms, as safety and efficacy have not been formally established.
  • Children who cannot swallow tablets whole must use the oral suspension formulation.
  • Older Adults do not require a dose adjustment based on age alone, but renal function monitoring is recommended.

Condition-Based and Conditional Use

  • Renal Impairment: Patients with markedly impaired renal function ( CrCl < 20 mL/min) require that the dosage be reduced to compensate for slower excretion.
  • Comorbidities: Caution is advised for those with a history of colitis. The oral suspension is cautioned in patients with Phenylketonuria (PKU) due to aspartame content. Safety is not established in patients with gastrointestinal malabsorption.
  • Pregnancy and Lactation: Use is conditional; the medicine should be administered only if clearly necessary and with caution, as Cefuroxime is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Oracef (Cephalexin, Cefpodoxime, or Doxycycline, depending on formulation) may interact with several medicinal products and substance classes, primarily affecting drug levels, the risk of side effects, or the efficacy of the interacting medicine.


Documented Interaction Categories

Interacting Product Category Key Interaction Mechanism or Result
Anticoagulants (e.g., Warfarin) Increased risk of bleeding, requiring monitoring of Prothrombin Time (PT) and INR.
Probenecid (Uricosuric agent) Competitively inhibits renal excretion of Cephalexin and Cefpodoxime, leading to higher and more prolonged antibiotic concentrations in the blood.
Metformin (Antidiabetic) Cephalexin can inhibit the renal clearance of Metformin, resulting in increased plasma concentrations of Metformin.
Oral Contraceptives Some cephalosporins (Cephalexin/Cefpodoxime) may reduce the effectiveness of hormonal birth control.
Antacids/H2 Receptor Antagonists Decrease absorption of Cefpodoxime and Doxycycline, reducing antibiotic effectiveness. Doses should be separated.
Nephrotoxic Agents/Potent Diuretics Concurrent use with drugs like aminoglycosides or potent diuretics (e.g., Furosemide) may increase the risk of kidney toxicity.
Iron/Mineral Supplements Can interfere with the absorption of Doxycycline, reducing its effectiveness. Dosing should be separated.

Other Constraints and Notes

Use of cephalosporins may cause a false-positive reaction for glucose in the urine when using copper-reduction methods and may cause a positive Direct Coombs’ Test. Ingestion of alcohol is advised to be avoided during and for a period after therapy with certain cephalosporins due to the potential for a disulfiram-like reaction.

Mechanism of Action

Molecular Mechanism: Irreversible Enzyme Inhibition

The primary action of Cefuroxime (Oracef) is to function as a covalent inhibitor against essential bacterial enzymes known as Penicillin-Binding Proteins (PBPs). These PBPs are critical for building the rigid protective peptidoglycan layer of the bacterial cell wall. By irreversibly binding to and deactivating these enzymes, the drug prevents the final necessary step of cell wall construction. This initial molecular binding sets the stage for the cell's destruction.


Bactericidal Action: Cell Wall Destabilization and Lysis

The inability to form a structurally intact cell wall leads to a rapid cascading effect: the bacterial cell loses its structural integrity and cannot withstand the high internal osmotic pressure. This physical failure results in the swift rupture (lysis) of the bacterial cell. This process is a targeted, bactericidal action that results in the elimination of the susceptible pathogen population, which is the functional consequence of the drug’s mechanism on the pathogen.


️ Constraint: Enzymatic Resistance

The mechanism's primary constraint is the presence of bacterial counter-mechanisms. Specifically, the drug's beta-lactam ring can be hydrolyzed and inactivated by bacterial enzymes called beta-Lactamases, which prevents the drug from reaching and inhibiting the PBPs. The existence of these enzyme mechanisms limits the physiological contexts in which Cefuroxime's bactericidal action applies.

Dosage and Administration Information

How to Use Oracef (Cefaclor) — Administration Instructions

The following details describe the administration of Cefaclor. This section contains usage details and does not include information on safety, indications, or mechanism of action.


Administration Details

Scope Requirement
Route of Administration Oral.
Standard Dosing Schedule (Adults) 250 mg every 8 hours, or 500 mg every 8 hours for severe infections. Some mild/moderate infections may use 250 mg every 12 hours.
Extended-Release (ER) Dosing 375 mg or 750 mg every 12 hours.
Pediatric Dosing 20 mg/kg/day to 40 mg/kg/day in divided doses, depending on the infection. Not proven safe for infants under one month.
Duration 7 to 10 days generally. Must be continued for a minimum of 10 days for beta-hemolytic streptococcal infections.

Specific Administration Protocol

Timing with Meals:

  • Capsules/Suspension (Standard): Can be taken with or without food.
  • Extended-Release Tablets: Must be taken within 1 hour of eating a meal every 12 hours. Extended-release tablets must be swallowed whole and should not be crushed or chewed.

Preparation:

  • Oral Suspension: The dry powder must be reconstituted by adding the specified amount of water and shaking thoroughly before use.

Special Cases:

  • Renal Impairment: Doses are usually not adjusted but monitoring is required.
  • Haemodialysis: A loading dose is given before the procedure, followed by smaller maintenance doses every 6 to 8 hours during interdialytic periods.

These requirements define the necessary procedural structure for taking the medicine, ensuring strict adherence to the regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Oracef

1. Evidence Landscape for Respiratory Tract Infections

Research into Cefuroxime for acute respiratory conditions, such as pneumonia, bronchitis, tonsillitis, and sinusitis, has been explored through Randomized Controlled Trials (RCTs) and systematic reviews. The research focused on data points related to physical discomfort and systemic or functional imbalance, such as measuring fever, cough, and other signs of infection. Research describes clinical and microbiological data points that were gathered from the observed populations. However, research exploring short-term symptom changes in certain mild conditions may be inconclusive or show limited difference from non-antibiotic approaches.

2. Evidence Landscape for Genitourinary Tract Infections

Cefuroxime was evaluated in trials that included cohorts with genitourinary conditions, such as uncomplicated urinary tract infections (UTIs) and pyelonephritis. The measured data included patient-reported changes in physical discomfort and laboratory results related to organism clearance. Research describes clinical data metrics that were gathered shortly after the study period finished. Research indicates that the applicability of findings from older comparative trials may be limited today due to potential shifts in bacterial resistance patterns.

3. Evidence Landscape for Early Lyme Disease

Cefuroxime was studied for use in early Lyme disease, which is typically identified by the Erythema Migrans rash. Key research includes high-quality comparative RCTs that primarily focused on adults and children with this early-stage presentation. The primary outcome axes included measurements tracking changes in the rash and systemic symptoms, along with long-term follow-up protocols that monitored patients for up to a year. However, the data applies only to the populations studied with early, localized disease and does not provide insight into patients with advanced or chronic manifestations.

4. Research Gaps and Remaining Uncertainties

Several research limitations are noted in the evidence landscape for Cefuroxime. Follow-up durations were limited to the short term for most indications, meaning there is limited information for long-term outcomes or the durability of the effect, except for specific research on early Lyme disease. Comparative evidence is lacking in some areas against the newest generation of anti-infective agents. Furthermore, ongoing changes in bacterial resistance patterns globally mean that the applicability of past study results may vary by geographic location and over time.

Key Studies & References

  1. FDA Label for CEFUROXIME AXETIL Tablets (Indications and Clinical Studies)
  2. Cefuroxime - StatPearls (General Evidence and Resistance Overview)

Frequently Asked Questions (FAQ)

Common questions about Oracef (FAQ)

Q: What kind of infections is Oracef most commonly used for?

A: According to official product information, Oracef (Cefuroxime) is used to address infections caused by susceptible bacteria. These typically include infections of the ears, sinuses, throat, tonsils, lower respiratory tract (such as bronchitis and pneumonia), skin and skin structure, and the urinary tract. It is also indicated for the treatment of early Lyme disease.

Q: Does Oracef treat viruses or only bacteria?

A: Oracef is classified as an antibiotic and is designed to eliminate susceptible bacteria by disrupting their cell walls. Regulatory warnings state that this medication will not work for infections caused by viruses, such as the common cold or flu. Regulatory warnings state that using the antibiotic for conditions not caused by susceptible bacteria may contribute to the development of drug resistance.

Q: How quickly does Oracef start working after taking it?

A: Official drug information indicates that a patient may begin to notice an improvement in their symptoms within the first few days of treatment. If symptoms do not start to improve or if they worsen during this time, a healthcare provider should be consulted.

Q: How long do the effects of one dose of Oracef last?

A: The typical oral dosing schedule for Oracef is generally every 12 hours. This schedule is established based on official data showing how long the active drug is expected to maintain effective levels in the body to manage the infection.

Q: Can Oracef cause an allergic reaction, and what are the signs?

A: Yes, Oracef can cause allergic reactions, including severe ones like anaphylaxis, which requires immediate medical attention. Less severe signs of a reaction reported in official documents include rash, hives (urticaria), pruritus (itching), or fever. Official prescribing information notes that a known severe allergy to Cefuroxime or other beta-lactam drugs, such as penicillins, is a contraindication.

Q: Are there any specific vitamins or supplements that interact with Oracef?

A: Regulatory documents do not list major or moderate interactions for common multivitamin supplements. However, patients are generally advised to inform their healthcare providers about all concurrent treatments, including vitamins and supplements, to ensure comprehensive review of the treatment plan.

Q: What official warnings or black boxes are associated with Oracef?

A: Oracef (Cefuroxime) does not carry a formal Black Box Warning from the FDA. However, the label contains several serious safety warnings. These include the potential for severe allergic reactions, the risk of developing Clostridium difficile-associated diarrhea (CDAD), and cautions about the overgrowth of other organisms.

Q: Is Oracef considered safe for people with kidney issues?

A: Cefuroxime is primarily eliminated from the body through the kidneys. For patients with markedly impaired renal function, official prescribing information states that a dose reduction may be required. This adjustment helps to compensate for the drug being cleared slower from the body.

Q: Is there a different name for Oracef in other countries?

A: Yes, the active ingredient in Oracef, Cefuroxime, is a recognized International Non-proprietary Name (INN) and is sold under many different brand names globally. These brands can include Ceftin and Zinacef, and the drug is also commonly available as a generic medicine.

Q: What is the purpose of taking Oracef for skin infections?

A: According to official indications, Cefuroxime is used to treat bacterial infections involving the skin and underlying soft tissues. Its role is to eliminate the susceptible bacterial organisms that are causing the infection in the affected area.

Q: Are there studies showing how Oracef is used for ear infections?

A: Yes, the official product information indicates that Cefuroxime is included for addressing bacterial infections of the ears, such as acute otitis media. The drug is used to eliminate the susceptible bacteria causing the infection in the middle ear.

Q: How do medical professionals decide if Oracef is appropriate for an infection?

A: Regulatory guidance indicates that medical professionals should use Oracef only to address infections that are proven or strongly suspected to be caused by susceptible bacteria. This decision is often supported by laboratory results, such as culture and susceptibility testing, to ensure the antibiotic is appropriate for the specific pathogen.

Q: What happens if a dose of Oracef is missed?

A: Official drug information provides specific, non-personalized instructions for handling a missed dose. These instructions outline the procedure for when to take the dose or when to skip it, and should be reviewed and followed closely.

Q: Can Oracef cause sensitivity to sunlight?

A: Photosensitivity, or unusual sensitivity to sunlight, is not listed as a common or known side effect in the official regulatory labeling for Cefuroxime. The label does, however, list general skin reactions like rash and hives.

Q: Is it normal to feel tired while taking Oracef?

A: Official regulatory documents do not list general fatigue or tiredness as a common adverse reaction for Cefuroxime. However, common adverse reactions affecting the nervous system include headache and dizziness.

Q: What foods should be avoided while on Oracef?

A: Standard tablets or the oral suspension can be taken with or without food. Official instructions for the extended-release tablets are specific: they must be taken within one hour of eating a meal for best absorption. No other specific food types are generally restricted.

Q: What does the FDA say about Oracef's safety profile?

A: The FDA label details the complete safety profile of Oracef, based on clinical trials and postmarketing surveillance. This profile includes information on common side effects (e.g., diarrhea, nausea) and critical safety warnings regarding severe hypersensitivity reactions and the risk of developing a serious colon infection (CDAD).

Q: How is Oracef usually excreted from the body?

A: Cefuroxime is primarily eliminated from the body by the kidneys. It is excreted mostly unchanged in the urine through processes known as glomerular filtration and tubular secretion. Most of the drug is typically cleared within 24 hours.

Q: Why do some people experience yeast infections when taking Oracef?

A: Official warnings state that Oracef, like all antibiotics, can alter the body’s normal microbial balance. This change in the body's natural flora can sometimes lead to the overgrowth of organisms that are not susceptible to the drug, such as yeast (Candida), resulting in conditions like vaginitis.

Q: Does Oracef work against MRSA?

A: Official information regarding the mechanism of resistance indicates that Cefuroxime is generally not effective against Methicillin-resistant Staphylococcus aureus (MRSA). MRSA has a specific resistance mechanism that limits the effectiveness of many beta-lactam antibiotics, including Cefuroxime.

Q: Can Oracef be used for prevention of infections (prophylaxis)?

A: Yes, Cefuroxime has an official indication for surgical prophylaxis. This means the medicine is authorized for use before, during, and sometimes immediately after certain surgical procedures to prevent potential bacterial infections from developing.

Q: How does Oracef affect the 'good bacteria' in the gut?

A: The official product labeling indicates that treatment with Oracef can alter the normal flora (the community of bacteria) in the colon. This alteration is what sometimes leads to issues like C. difficile overgrowth or diarrhea, as the balance of organisms is disrupted.

Q: What are the limitations of Oracef as described in official prescribing information?

A: The official prescribing information describes several limitations, including the contraindication for patients with a known allergy to beta-lactam drugs, and cautions regarding reduced efficacy if used inappropriately. It also outlines the need for dose adjustments in patients with significant kidney impairment.

Q: Is Oracef often used as a first-line treatment or second-line?

A: Regulatory documents do not categorize the drug as universally first- or second-line, as this depends on the infection being addressed. However, Cefuroxime is noted in research and official guidance as one of the recommended oral antibiotics for addressing specific conditions, such as early Lyme disease.

Q: Can Oracef cause changes in mood or sleep?

A: Changes in mood or sleep are not listed as common adverse reactions in the official labeling. However, serious neurotoxic reactions, such as convulsions (seizures), have been reported. These reactions are primarily associated with the drug accumulating in the body due to severe kidney impairment.

Q: Are there generic versions of Oracef available?

A: Yes, the active ingredient in Oracef, which is Cefuroxime axetil, is widely available in generic tablet and suspension forms. Generic medicines contain the same active ingredient and are expected to work in the same way as the brand-name product.

Q: What types of bacteria is Oracef generally effective against?

A: According to the microbiology sections of the regulatory label, Cefuroxime is effective against a broad range of Gram-positive and Gram-negative organisms. It is used against specific species that are known to cause infections in the respiratory, ear, skin, and urinary tracts.

How should Oracef be stored and disposed of?

How to Store and Dispose of Cefuroxime (Oracef)

Cefuroxime tablets and the powder for oral suspension must be stored at controlled room temperature (20 C to 25 C) and protected from moisture, kept in the original, tightly closed container. The reconstituted oral suspension requires storage under refrigeration (2 C to 8 C) and must not be frozen.

Stability and Safety

The refrigerated suspension is stable for 10 days, and any unused portion must be discarded after this period. All forms of this medication must be stored out of the sight and reach of children.

Disposal

Unused or expired product should be disposed of via an authorized drug take-back program. If a program is unavailable, mix the medication with an undesirable substance, seal it, and discard it in the household trash. Do not flush Cefuroxime down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oracef found in:

A-Z Index: